UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2025
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
15
December 2025 - “Board and Committee
Changes”
|
99.1
Haleon plc: Board and Committee Changes
15 December 2025: Haleon
plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces
that Alan Stewart will succeed Vindi Banga as Senior Independent
Director ("SID"), upon Vindi's appointment as Chair with effect
from 1 January 2026.
Alan Stewart joined the Board as a Non-Executive Director and Chair
of the Audit & Risk Committee in September 2024. Alan will
remain Chair of the Audit & Risk Committee and a member of the
Remuneration Committee, Nominations & Governance Committee and
Environmental & Social Sustainability Committee following his
appointment as Senior Independent Director.
In accordance with the UK Corporate Governance Code 2024, Vindi
will step down as a member of the Audit & Risk Committee
effective 31 December 2025. Vindi will also step down as a member
of the Remuneration Committee effective 31 December 2025 and be
appointed Chair of the Nominations & Governance Committee
effective 1 January 2026.
Further to the announcement on 10 November 2025, the Company
confirms that Vindi Banga's remuneration as Chair will be
£757,103 per annum. Further details will be disclosed in the
Company's 2025 Annual Report & Accounts.
The Company confirms that there is no further information to be
disclosed under the requirements of UKLR 6.4.6R.
Amanda Mellor
Company Secretary
Enquiries
|
Investors
|
Media
|
||
|
Jo
Russell
|
+44
7787 392441
|
Zoë Bird
|
+44
7736 746167
|
|
Rakesh
Patel
|
+44
7552 484646
|
Victoria
Durman
|
+44 7894 505730
|
|
Email: [email protected]
|
Email: [email protected]
|
||
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans six major categories - Oral Health,
Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory
Health, Digestive Health and Therapeutic Skin Health and Other. Its
long-standing brands - such as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne,
Theraflu and Voltaren - are built on trusted science, innovation
and deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date:
December 15, 2025
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|